Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT study of Pritelivir in healthy subjects
NCT05671029Phase 1Completed
- Sponsor
- AiCuris
- Start
- Dec 2022
- Primary completion
- May 2023
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pritelivir in herpes simplex virus infection (3 arms), sponsored by AiCuris. Primary endpoint: Effects of Pritelivir on the QTcF Interval. Started Dec 2022; status: completed.
02
Drugs
pritelivir
03
Conditions
herpes simplex virus infection
Beyond the preview
Go deeper on NCT05671029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05671029.